At Aegis, scientific knowledge is a core value and a core competence.

For over a decade, Aegis Creative has been contributing to the successful development and market implementation of innovative drug therapies that use novel pathways and have unique mechanisms of action (MOAs) in the focus areas of hematology, immunology, molecular biology, neurology, oncology and, ophthalmology.

The Aegis team has exemplary skills and experience because they:

• Have a deep understanding of the science behind novel, targeted therapeutics and strategies associated with products at all phases of the product lifecycle
• Hold clinical and advanced degrees in the hard sciences, including molecular biology, genetics, and genomics, and can listen to subtleties in advisor conversations and communicate efficiently with key opinion leaders (KOLs)
• Have been awarded patents in various biotechnology applications, illustrating their knowledge and commitment to innovation
• Have knowledge of compliance issues and regulations and can help mitigate your risk in an increasingly regulated environment

Our team’s experience, education, and knowledge mean that we require minimal orientation and management. Additionally, our team members are full-time employees of Aegis, allowing us to build a history of knowledge of our clients’ scientific platforms, products, KOLs, and competition.

Having a highly educated staff, while a prerequisite, is not enough on its own to produce uncommon results. We understand the array of efforts required to successfully research, develop, test, and market innovative, complex drug therapies because we have worked with some of the most successful products on the market today.

To learn more, contact Jasmine Martin, VP Education & Advisory Board Services, for an in-depth discussion of our skills and capabilities.